The pilot study of SGLT2 selective inhibitor therapy for NAFLD patients who were complicated with T2DM

The pilot study of SGLT2 selective inhibitor therapy for NAFLD patients who were complicated with T2DM - The pilot study of SGLT2 selective inhibitor therapy for NAFLD patients who were complicated with T2DM

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023574

Enrollment

Registered

2016-08-09

Start date

2014-10-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD patients who were complicated with T2DM

Interventions

Administration of 6 months of selective SGLT2 inhibitor.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-alcoholic fatty liver disease patients complicated with type 2 diabetes.

Exclusion criteria

Exclusion criteria: Chronic liver disease cases other than the non-alcoholic fatty liver disease.

Design outcomes

Primary

Measure	Time frame
HbA1c after 6 months from the start of the administration.	—

Secondary

Measure	Time frame
Body weight, body composition, ASTand ALT after 6 months from the start of the administration.	—

Countries

Japan

Contacts

Public ContactHiroshi Tobita

Shimane University Hospital Department of Hepatology

ht1020@med.shimane-u.ac.jp0853-20-2190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026